Northwest Biotherapeutics (NWBO) Notes Payables (2010 - 2026)

Northwest Biotherapeutics' Notes Payables history runs 17 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• In Q1 2026, Notes Payables rose 1024.52% year-over-year to $11.6 million; the TTM figure through Mar 2026 stood at $11.6 million (up 1024.52% YoY), while the FY2025 annual figure was $9.5 million, up 326.68% from the prior year.
• Notes Payables for Q1 2026 stood at $11.6 million, up from $9.5 million in the prior quarter.
• The five-year high for Notes Payables was $98.6 million in Q1 2022, with the low at $913000.0 in Q1 2024.
• The 5-year median for Notes Payables is $8.9 million (2024), against an average of $19.4 million.
• The sharpest annual moves came in 2023 and 2026: Notes Payables tumbled 98.62% in 2023, then jumped 1024.52% in 2026.
• Northwest Biotherapeutics' Notes Payables stood at $15.4 million in 2022, then plunged by 93.87% to $944000.0 in 2023, then jumped by 135.06% to $2.2 million in 2024, then jumped by 326.68% to $9.5 million in 2025, then grew by 23.05% to $11.6 million in 2026.
• Business Quant data shows NWBO's Notes Payables at $11.6 million in Q1 2026, $9.5 million in Q4 2025, and $13.6 million in Q3 2025.